Furthermore, significantly higher PPARγ mRNA was observed in primary AML patients.63 Therefore, in addition to revealing the contribution of epigenetic- and PPARγ-mediated inactivation of CEBPD in leukemic cells, the issue of how to efficiently activate CEBPD for executing its tumor suppressor role in leukemia remains an open question. This evidence concerns the gene PPARG and acute myeloid leukemia.